Executive record

George Mclean Milne Jr., Ph.D.

Director at Amylyx Pharmaceuticals, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:george-mclean-milne-jr-ph-dVersion: public-0As of: 2026-09-28

Not yet claimed21 published Claims9 sources
  • Director

Key Claims

Biography

Dr. Verdine is one of Wave's founders and has served as a director since July 2013, previously serving as President, CEO and CSO. He is the Erving Professor of Chemistry, Emeritus at Harvard University and has co-founded numerous biopharmaceutical companies.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Chief Scientific Officer · Organization not publishedNUVB DEF 14A executive officers
  2. 2026 to end not publishedExecutive title: Vice President, Science and Chief Scientific Officer · Organization not publishedOMER 10-K executive officers
  3. 2026 to end not publishedExecutive title: Executive Vice President and Chief Human Resources Officer · Organization not publishedBIIB 10-K executive officers
  4. 2025 to end not publishedExecutive title: Director · Organization not publishedWVE DEF 14A executive officers

Claims

Conflicts and accountability

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

9 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. AMLX DEF 14A director slate

    sec filing · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Board role: Board role: Chair · Claim reviewed: Apr 24, 2026
    • Committee assignments: Committee assignments: Audit, Compensation, Nominating/Governance, Science/Innovation · Claim reviewed: Apr 24, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026

  2. Amylyx Pharmaceuticals, Inc. director board source

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 3, 2026

    Supports 3 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  3. Open source

    sec proxy · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026

  4. NUVB DEF 14A executive officers

    sec filing · Source published: Apr 10, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at Nuvation Bio Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 5, 2026

  5. OMER 10-K executive officers

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at OMEROS CORP · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Vice President, Science and Chief Scientific Officer · Claim reviewed: May 5, 2026

  6. BIIB 10-K executive officers

    sec filing · Source published: Feb 6, 2026 · Retrieved: Apr 29, 2026

    Supports 2 claims
    • Executive company: Executive at Biogen Inc. · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Executive Vice President and Chief Human Resources Officer · Claim reviewed: May 3, 2026

  7. WVE DEF 14A executive officers

    sec filing · Source published: Jun 23, 2025 · Retrieved: May 5, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Executive company: Executive at Wave Life Sciences Ltd. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 5, 2026
    • Other Company Role: Gregory L. Verdine, Ph.D. is also linked to LifeMine Therapeutics Inc. as President and Chief Executive Officer. · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026

  8. BIIB executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise reported in filings · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Biogen Inc. · Claim reviewed: May 3, 2026
    • Executive function: People Talent (CHRO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Executive Vice President and Chief Human Resources Officer · Claim reviewed: May 3, 2026

  9. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026